ZIVO Bioscience 9/2/2026 Earnings Report

ZIVO Bioscience EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.28
• Beat/Miss: N/A
• One Year Ago EPS: N/A

ZIVO Bioscience Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $0.20 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

ZIVO Bioscience Announcement Details

• Date: 9/2/2026
• Time: After Market Closes
• Conference Call Date: N/A
• Conference Call Time: N/A

ZIVO Bioscience (NASDAQ:ZIVO) is a clinical-stage biotechnology company focused on developing precision live biotherapeutics to prevent and treat gastrointestinal infections in both animal and human health markets. The company applies synthetic biology, microbiology and fermentation technologies to engineer proprietary bacterial strains that produce targeted lactic acid and antimicrobial compounds. Its pipeline includes ZB-01, an orally administered therapy for recurrent Clostridioides difficile infections in humans, and ZB-02, a feed-additive candidate aimed at reducing Salmonella colonization in poultry.

Founded in 2016 and headquartered in Carlsbad, California, ZIVO Bioscience leverages exclusive licensing agreements with academic institutions to advance its lead programs through preclinical and early clinical development. The company’s animal health platform is designed to offer an antibiotic‐free approach to controlling foodborne pathogens, while its human health efforts target high-unmet-need gastrointestinal diseases where current therapies fall short or carry significant safety risks.

ZIVO’s proprietary fermentation processes are scalable and designed to meet regulatory standards for both veterinary and human therapeutics. The company collaborates with contract development and manufacturing organizations (CDMOs) to produce its live bacterial formulations under Good Manufacturing Practices (GMP). These partnerships aim to accelerate the transition of ZIVO’s pipeline assets from research to first-in-human trials and commercial supply.

Under the leadership of CEO Jon Bany, ZIVO Bioscience continues to build a multidisciplinary team of experts in microbiology, immunology and process development. The company’s strategic focus on dual animal and human health applications reflects a growing industry emphasis on microbiome-based solutions that improve public health outcomes while addressing regulatory pressures to reduce antibiotic use in agriculture.